Amgen inks $180M nanomedicine deal
Thousand Oaks-based Amgen has entered a deal to pay up to $180.5 million for nanomedicine tumor treatments being developed by a Massachusetts company. Cambridge-based Bind Biosciences said it has entered a development agreement with Amgen for its kinase inhibitor nanomedicines for treating a range of solid tumors. The medicines are highly targeted and can be Read More →
Nexsan sold for $120M
Thousand Oaks-based Nexsan Corp., a maker of hard-disk storage arrays for mid-sized businesses, has been purchased by Imation Corp. for $120 million. Imation will pay $105 million in cash and 3.3 million common shares, worth about $15 million, for the Thousand Oaks firm. Nexsan is privately held but kicked off an unsuccessful bid to go Read More →
CalAmp buys Wireless Matrix for $53M
Oxnard-based wireless products company CalAmp Corp. said Dec. 20 that it is buying the U.S. operations of Wireless Matrix Corp. for $53 million in cash. CalAmp said it expects the deal, which will likely close in the first quarter of 2013, to be accretive to its non-GAAP earnings starting in 2014. Wireless Matrix is a Read More →
QAD buys Michigan firm for $5M
Santa Barbara-based manufacturing software firm QAD said Dec. 31 that it purchased Michigan-based Cebos for $5 million in cash. QAD sells planning and management software used by large manufacturing firms around the world. Cebos provides management and regulatory compliance software. QAD will pay $3.5 million upon closing the deal and then $1.5 million subject to Read More →
French Hospital on track with $39M upgrade
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen to pay $150M for misbranding Aranesp
[Editor’s note: This story has been updated with comments from Amgen.] Biotech giant Amgen pleaded guilty Dec. 18 to a misdemeanor charge for misbranding its anemia drug Aranesp. According to a report from Bloomberg News, the Thousand Oaks-based firm agreed to pay $150 million in fines and penalties as part of the guilty plea. U.S. Read More →
